Carmen Ghilardi

List of Publications by Year
in descending order

18	620	623734	752698
papers	citations	14 h-index	20 g-index

22	22	22	1291
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. Cancer Research, 2014, 74, 6980-6990.	0.9	110
2	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics, 2008, 9, 201.	2.8	56
3	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	5.9	51
4	Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Molecular Cancer Therapeutics, 2004, 3, 111-21.	4.1	46
5	Thrombospondinâ€1 is part of a Slugâ€independent motility and metastatic program in cutaneous melanoma, in association with <scp>VEGFR</scp>â€1 and <scp>FGF</scp>â€2. Pigment Cell and Melanoma Research, 2015, 28, 73-81.	3.3	45
6	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. Experimental Cell Research, 2000, 258, 384-394.	2.6	43
7	Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumorâ€™s proangiogenic microenvironment. Cellular and Molecular Life Sciences, 2012, 69, 1167-1178.	5.4	40
8	Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget, 2015, 6, 3043-3054.	1.8	38
9	A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. ELife, 2019, 8, .	6.0	38
10	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. Neoplasia, 2012, 14, 846-IN16.	5.3	28
11	VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. Journal of Hematology and Oncology, 2021, 14, 186.	17.0	27
12	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. Angiogenesis, 2017, 20, 233-241.	7.2	22
13	Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical and Experimental Metastasis, 2010, 27, 43-53.	3.3	18
14	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. Endocrinology, 2010, 151, 4643-4653.	2.8	15
15	PGC1Î±/Î² Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. Cancer Research, 2022, 82, 1423-1434.	0.9	14
16	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget, 2015, 6, 28389-28400.	1.8	13
17	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. Molecular Cancer Therapeutics, 2022, 21, 555-567.	4.1	11
18	Anticancer Therapy with Angiogenesis Inhibitors. Tumori, 2001, 87, 14-16.	1.1	1